ProSomnus SPAC Presentation Deck

ProSomnus is Changing the Way OSA is Treated ProSomnus is the first manufacturer of precision, mass-customized OAT devices KEY ATTRIBUTES ProSomnus precision devices are individualized to match the patient's anatomy and treatment plan with precision (less than 0.5 millimeters variance to the prescription) Precision enables better effectiveness, fewer side effects and greater patient satisfaction i Clinically-proven to be more effective with better adherence than other treatment alternatives¹ Platform for remote monitoring of key physiological and therapeutic metrics Reimbursed by private medical insurance and Medicare Scalable, digital manufacturing platform 2019 Inc. 5000 LIST 2019 S FASTEST 2020 T-GROWING 2020 Inc. Inc. 5000 5000 LIST PRIVATE COMPANIES 20 CE FDA U.S.ARMY UNITED STATES PATENT AND TRADEMARK OFFICE uspto PROSOMNUS TO DATE 150,000+ Patients Treated to Date $14 Million 2021 Net Revenue ~70% 2021 Revenue Growth & 2021-2023E Revenue CAGR PROSOMNUS SLEEP TECHNOLOGIES ProSomnus EVO Most Prescribed OAT Device in the United States 1. Effectiveness defined as efficacy times adherence 2. Benjafield AV et al. Estimation of the global prevalence and burden of obstructive sleep apnea: a literature-based analysis. Lancet Respir Med. 2019 Aug 7. cites that as of 2019 an estimated 936 million adults aged 30-69 have mild to moderate OSA, as such we estimate >1 billion global OSA sufferers 3. Assumes 32% prevalence of OSA (Benjafield et al. 2019 Aug 7), multiplied by North American adult population of approximately 230 million as provided by OECD 4. Diagnosis rate of 20%, cited in Harvard Medical School. THE PRICE OF FATIGUE. December, 2010, with assumed increase of approximately 400 basis points by 2020. ~80% CPAP modality prescription rate cited in same Harvard study 5. Represents North American market failures of ~50% cited in Catcheside PG. Predictors of continuous positive airway pressure adherence. F1000 Med Rep. 2010 Sep 23 6. Calculated as ~70mm sufferers (Benjafield et al. 2019 Aug 7) multiplied by estimated diagnosis rate of ~24% (20% citied in Harvard. December 2010), multiplied by the CPAP modality prescription rate of 80% (Harvard: December 2010), multiplied by the CPAP therapy failure rate of 50% (Catcheside PG. 2010 Sep 23) LARGE, UNDERSERVED MARKET OPPORTUNITY 1+ Billion Global OSA Sufferers² 70+ Million North American OSA Sufferers³ 7+ Million North American CPAP Failures4,5,6 5 STRICTLY CONFIDENTIAL

View entire presentation